BioSpace News Archive

GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced today that its subsidiary, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its digital application, aPROMISE™ (automated PROstate Cancer Molecular Imaging Standardized Evaluation). Clinicians will have the option to utilize aPROMISE with PYLARIFY®

Centene Corporation announced that it has priced its previously announced underwritten public offering of $1,800,000,000 aggregate principal amount of senior notes.

Neukio Biotherapeutics, a newly established company, recently announced the completion of its $40m Angel round of financing led by Lilly Asia Venture (LAV), with the participation of IDG Capital and Sherpa Investments.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an update on its pipeline of late-stage product candidates, and an activity report for the fourth quarter ended June 30, 2021.

RxSight, Inc., an ophthalmic medical device company, announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share.

Immuneering Corporation announced the pricing of its upsized initial public offering of 7,500,000 shares of Class A common stock at a public offering price of $15.00 per share, for total gross proceeds of $112.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering.

Tenaya Therapeutics, Inc., a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced the pricing of its underwritten, upsized initial public offering of 12,000,000 shares of its common stock at an initial public offering price of $15.00 per share.

Kane Biotech Inc. announces that it has received two Decisions to Grant from the European Patent Office for patents covering its best-in-class coactiv+™ technology.

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that it will report second quarter 2021 financial results and provide a corporate update before market open on Thursday, August 5, 2021.